Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

- Exclusive collaboration and license agreement for povetacicept in these countries -
- Ono will leverage its deep expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate advancement of povetacicept for patients with IgA nephropathy and primary membranous nephropathy -
BOSTON & OSAKA, Japan, June 23, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other B cell-mediated diseases.
Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications.
"Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases."
"Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono," said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. "We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment."
About Povetacicept
Povetacicept is a recombinant fusion protein therapeutic and a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and calcium modulator ligand interactor) domain, povetacicept has higher binding affinity and greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and has demonstrated potential best-in-class efficacy in a clinical trial in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also in development for multiple serious B cell-mediated diseases including other autoimmune kidney diseases and autoimmune cytopenias.
About IgA Nephropathy (IgAN)
IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years. There are no approved therapies that specifically target the underlying cause of IgAN.
About Primary Membranous Nephropathy (pMN)
Primary membranous nephropathy is a serious, progressive, life-threatening B cell-mediated chronic kidney disease affecting people worldwide, with approximately 150,000 people diagnosed in the U.S. and Europe. It is estimated that there are approximately 6,000 diagnosed patients with pMN in Japan. pMN is a rare glomerular disease that occurs when the body generates an abnormal immune response, including autoantibodies, against proteins that are part of the kidney. Autoantibodies trigger damage and inflammation, especially within the glomeruli (the parts of the kidney that filter blood), impairing the kidneys' ability to properly filter waste and fluid, eventually causing progressive loss of kidney function. There are no approved therapies that specifically target the underlying cause of pMN.
About RAINIER
RAINIER is a global Phase 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating urine protein to creatinine ratio (UPCR) for the povetacicept arm versus placebo after a certain number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104.
The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway.
About RUBY-3
RUBY-3 is an ongoing, multiple ascending dose, multi-cohort, open label, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis, including IgAN, primary membranous nephropathy, lupus nephritis and ANCA-associated vasculitis with glomerulonephritis where povetacicept is being administered subcutaneously for up to 104 weeks.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
About Ono Pharmaceutical Co., Ltd
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of "Dedicated to the Fight against Disease and Pain," Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.
Vertex Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani M.D., and Toichi Takino, in this press release, and statements about the terms of and expectations for Vertex's collaboration with Ono, statements about potential benefits and results that may be achieved through the collaboration, statements regarding the future activities of the parties pursuant to the collaboration, including Ono's help to advance clinical trials and Ono's responsibility to obtain marketing authorizations in Japan and South Korea and to commercialize povetacicept in the regions, statements regarding upfront and milestone payments, and potential royalties on future products, and statements about Vertex's plans and expectations for the RAINIER and RUBY-3 clinical trials and potential plans to seek accelerated approval in the U.S. based on interim analysis from the RAINIER trial. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of the collaboration between Vertex and Ono may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading "Risk Factors" in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at www.vrtx.com and on the SEC's website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
(VRTX-GEN)
Ono Forward-Looking Statements
In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250623239210/en/
Contacts
Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.com Media: mediainfo@vrtx.com orInternational: +44 20 3204 5275orU.S.: 617-341-6992orHeather Nichols: +1 617-839-3607Ono Pharmaceutical Co., Ltd. Corporate Communications public_relations@ono-pharma.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

an hour ago

• Bloomberg

Morgan Stanley Collects $3.2 Billion for Middle Market Deals

Middle-market focused Morgan Stanley Capital Partners has collected $3.2 billion for its latest buyout fund amid a tough fundraising market for private equity firms. The fund, North Haven Capital Partners VIII, will back companies with earnings of between $20 million and $30 million, according to Morgan Stanley Investment Management 's Aaron Sack. The latest fund added several new investors from Asia and the Americas and is about 60% bigger than the last vehicle, Sack said.

Yahoo

an hour ago

• Yahoo

Core Gaming Showcases Technological Strength as AI App Gains Traction

Viral Sharing of AI COMIC on TikTok and Facebook Signals Strong User Adoption and Community Engagement User Base in Japan and South Korea Grows 1,300%, Underscoring Commercial Success and Global Potential Cutting-Edge AI Capabilities and Smart Cloud Infrastructure are Foundation for Growth VANCOUVER, BC, June 23, 2025 /PRNewswire/ -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) ("Siyata" or the "Company"), a global developer and vendor of mission-critical Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that Core Gaming, a rising innovator in AI-driven creative technologies, who it recently signed a definitive merger agreement with, is experiencing continued momentum with its innovative AI COMIC app. In less than one year, combined user numbers of AI COMIC in Japan and South Korea have jumped from 2,500 to over 32,000, a 13x increase, while those countries' share of total global users rose from 4.12% to 14.38%. "AI COMIC's breakout success in Japan and South Korea is a powerful validation of our strategic vision," said Aitan Zacharin, CEO of Core Gaming. "Return on investment in the region has more than tripled, driven by targeted localization efforts such as a language-optimized user interface. Just as important, the virality we are seeing through widely used platforms like TikTok and Facebook underscores how deeply users are engaging with our product." Launched to broad interest, AI COMIC blends next-gen AI capabilities with a uniquely immersive user experience. The app empowers users to transform everyday visuals into vivid anime-style content through features such as AI-generated video, personalized avatars, manga scene recreation, time-lapse aging and realistic face swaps. Zacharin continued, "AI COMIC runs on a robust technological foundation built on our proprietary Compute Pool System, multimodal generative AI models and a scalable cloud orchestration architecture that is redefining content creation and distribution. Importantly, our goal is not just to build apps. We are building a robust, scalable AI infrastructure designed to power creative expression on a global scale. AI COMIC is only the beginning." Technology Platform: A Breakthrough AI Engine While AI COMIC continues to attract headlines and users, the underlying technology is the true differentiator. To support rapid growth and creative demand, Core Gaming built a smart, cloud- based infrastructure that delivers scalable AI performance while keeping costs efficient. This foundation enables the platform to streamline game asset creation—from automated scene and character generation to fast, high-quality animations and ad creatives—helping content teams iterate faster and bring ideas to life with minimal effort. Core Gaming's AI infrastructure is designed around three core pillars: Compute Pool System (CPS) is a dynamic AI task distribution engine that allocates computational resources across workloads in real time. CPS ensures optimal throughput for video generation, avatar rendering and real-time user interactions—without overprovisioning infrastructure. Multimodal Generative Models that process and synthesize visual, text and audio inputs simultaneously, enabling complex creative outputs such as dialogue-driven animation, mood-based styling, and high-resolution content generation tailored to the user's intent. Proprietary BigP Backend and Cloud Orchestration serves as the orchestration layer for model training, inference pipelines and content delivery. Integrated with a globally distributed cloud framework, it scales elastically to meet creative surges whether from new user spikes or major feature rollouts. "AI COMIC is just one example of what our platform can do," Zacharin continued. "Our AI infrastructure is built for scale to transform workflows across a multitude of use cases including gaming, marketing, education and enterprise content. By automating the most time-consuming parts of creation, we empower teams to focus on storytelling and strategy. The momentum we are experiencing in Japan and South Korea is a clear signal that our technology can shape the future of creative expression on a global scale." Zacharin concluded, "We continue to work diligently to finalize the merger with Siyata and remain confident that we will secure regulatory approval in the near future, with closing expected shortly thereafter." About Core Gaming, Inc. Core Gaming is an international AI driven mobile games developer and publisher headquartered in Miami. We create entertaining games for millions of players worldwide, while empowering other developers to deliver player-focused apps and games to enthusiasts. Core's mission is to be the leading global AI driven gaming company. Since our launch we have developed and co-developed over 2,100 games, driven over 780 million downloads, and generated a global footprint of over 40 million users from over 140 countries. Visit to learn more. About Siyata Mobile Inc. Siyata Mobile Inc. is a B2B global developer and vendor of next-generation Push-To-Talk over Cellular handsets and accessories. Its portfolio of rugged PTT handsets and accessories enables first responders and enterprise workers to instantly communicate over a nationwide cellular network of choice, to increase situational awareness and save lives. Police, fire, and ambulance organizations as well as schools, utilities, security companies, hospitals, waste management companies, resorts and many other organizations use Siyata PTT handsets and accessories today. In support of our Push-to-Talk handsets and accessories, Siyata also offers enterprise-grade In- Vehicle solutions and Cellular Booster systems enabling our customers to communicate effectively when they are in their vehicles, and even in areas where the cellular signal is weak. Siyata sells its portfolio through leading North American cellular carriers, and through international cellular carriers and distributors. Siyata's common shares trade on the Nasdaq under the symbol "SYTA", and its common warrants trade on the Nasdaq under the symbol "SYTAW". Visit to learn more. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Siyata's filings with the Securities and Exchange Commission ("SEC"), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites and social media have been provided as a convenience, and the information contained on such websites or social media is not incorporated by reference into this press release. View original content to download multimedia: SOURCE Siyata Mobile Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

2 hours ago

• Yahoo

Impact of India's large rate cut may be limited, says rate panel member

By Swati Bhat MUMBAI (Reuters) -The immediate incremental impact of an additional 25 basis-point rate cut delivered earlier this month by the Reserve Bank of India's monetary policy committee may be relatively limited, external member Saugata Bhattacharya told Reuters on Monday. The MPC delivered a larger-than-expected 50-bp rate cut in June to bolster economic growth as inflation remained below target. "Interest rates transmission also works through a transfer of disposable incomes across various economic stakeholders," Bhattacharya, the only member to vote for a 25-bp rate cut said while sharing his personal views. He said the most crucial shift will be to micro, small and medium enterprises (MSME) and home loan borrowers from retail depositors. "These shifts are likely to accumulate over the course of the year. How the relative marginal propensities to consume and save play out will determine inter alia changes to the credit multiplier and hence deposit and loan growth," he added. Bhattacharya said inflation is likely to align with the RBI's 4% target on a durable basis in the coming quarters. "Although the overall picture remains mixed, many high-frequency economic indicators also suggest continuing growth resilience," he said, adding that the RBI's forecast of GDP growth at 6.5% for fiscal year 2026 precluded the need for a deeper rate cut given current global uncertainty. There may be space for more "good news" rate cuts, but Bhattacharya said he would "prefer a more gradual and calibrated path over this easing cycle". The RBI's June policy actions should be seen as a step towards propelling growth to a higher aspirational trajectory, Governor Sanjay Malhotra had said in a post-policy briefing, adding that the country would like to achieve 7%-8% growth. Bhattacharya said he would like to assess the effects on aggregate demand from the government's policy initiatives, particularly income tax cuts, as well as price and income support on demand revival. Bringing short-term money market rates and overnight rates a little closer to the floor of the monetary policy corridor is probably needed at this point to accelerate the transmission of the policy rate into bank lending and deposit rates, Bhattacharya said. Once transmission begins to align with the intended easing cycle, liquidity can then be calibrated, which the RBI has done in the past through various instruments to bring overnight rates closer to the policy rate, he added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data